Loading market dashboard
60 Degrees Pharmaceuticals, Inc.
SXTPHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.S. WASHINGTON, May 26, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or 60 Degrees Pharmaceuticals), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced that the first patient of the 2026 tick season has been enrolled in the randomized, double-blind, placebo-controlled clinical trial ( NCT06207370 ) to evaluate the efficacy and safety of tafenoquine in treating babesiosis in humans. The study, which will enroll at least 24 patients prior to an interim analysis, is being conducted at five clinical sites in the Northeastern United States.
Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of tafenoquine in treating humans hospitalized with babesiosis at five clinical sites in northeastern U.
WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026, ended March 31, 2026. Financial Highlights for the Quarter Ended March 31, 2026: Net product revenues decreased approximately 1% from $164 thousand for the first quarter of 2025 to approximately $162 thousand for the first quarter of 2026.
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP - Get Free Report) was the target of a significant decline in short interest during the month of March. As of March 31st, there was short interest totaling 160,681 shares, a decline of 66.9% from the March 15th total of 484,774 shares. Based on an average daily volume of 371,994
60 Degrees Pharmaceuticals Inc. (SXTP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, reported today its financial results for the 2025 fiscal year ended December 31, 2025. Financial Highlights for the Fiscal Year Ended December 31, 2025: Net product revenues increased 65% from $607.6 thousand in 2024 to $1.0 million in 2025, driven by rising sales, price increases, and fewer returns.
60 Degrees files NDIN with FDA for Australian Chestnut Extract; May 25 decision deadline. FSU capsule license option expands commercialization strategy.
60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) shares are down during Friday's premarket session. This follows a 9.6% decline, closing at $2.91 on Thursday.
All three patients in 60 Degrees Pharma's expanded access study were cured of relapsing babesiosis after tafenoquine treatment, supporting guideline review
